Kazia Therapeutics
$5.909876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$5.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.19 (-3.12%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell KZIA and other stocks, options, and ETFs commission-free!
About KZIA
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. Read More The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia. The listed name for KZIA is Kazia Therapeutics Limited American Depositary Shares.
CEO
Employees
—
Headquarters
Sydney, New South Wales (NSW)
Founded
1994
Market Cap
67.94M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
57.45K
High Today
$6.07
Low Today
$5.85
Open Price
$6.07
Volume
14.02K
52 Week High
$9.74
52 Week Low
$2.47
Collections
KZIA Earnings
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Nov 2, Pre-Market